Drs. Catherine Marshall, Melissa Reimers, and Tanya Dorff continue their discussion on toxicities from single-agent and combination-based HR inhibitors. The trio also predicts whether patients without HRR mutations will be able to receive PARP inhibitors in the future.
What are the essentials to know about toxicity from single agent and combination therapy HR inhibitors? Which patients should and should not receive combination therapy? Will there ever come a point when patients without HRR mutations should receive PARP inhibitors?
View their previous comments on Genetic Testing and PARP Inhibitors for Advanced Prostate Cancer.